Phenotypes Associated with This Genotype

Genotype
MGI:3850439

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Nf2^tm2Gth/Nf2^tm2Gth; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 80 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 100% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 47 of 51; rhabdomyosarcomas, 4 of 51; and schwannomas, 1 of 51)

• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased rhabdomyosarcoma incidence ( J:132943 )

increased mesothelioma incidence ( J:132943 )

• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased Schwannoma incidence ( J:132943 )

nervous system

increased Schwannoma incidence ( J:132943 )

muscle

increased rhabdomyosarcoma incidence ( J:132943 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943